169 related articles for article (PubMed ID: 2001539)
21. Treatment of metastatic malignant melanoma with 24 hours continuous venous infusion of dacarbazine and cisplatin.
Icli F; Karaoguz H; Dincol D; Gunel N; Demirkazik A
J Surg Oncol; 1991 Nov; 48(3):199-201. PubMed ID: 1943117
[TBL] [Abstract][Full Text] [Related]
22. Dibromodulcitol (DBD), DTIC, and actinomycin-D in disseminated malignant melanoma. A phase I-II clinical trial.
Samson MK; Haas CD; Baker LH; Cummings G
Am J Clin Oncol; 1985 Apr; 8(2):167-71. PubMed ID: 3834791
[TBL] [Abstract][Full Text] [Related]
23. GM-CSF with biochemotherapy (cisplatin, DTIC, tamoxifen, IL-2 and interferon-alpha): a phase I trial in melanoma.
Vaughan MM; Moore J; Riches PG; Johnston SR; A'Hern RP; Hill ME; Eisen T; Ayliffe MJ; Thomas JM; Gore ME
Ann Oncol; 2000 Sep; 11(9):1183-9. PubMed ID: 11061616
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study.
Margolin KA; Liu PY; Flaherty LE; Sosman JA; Walker MJ; Smith JW; Fletcher WS; Weiss GR; Unger JM; Sondak VK
J Clin Oncol; 1998 Feb; 16(2):664-9. PubMed ID: 9469356
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine.
Propper DJ; Braybrooke JP; Levitt NC; O'Byrne K; Christodoulos K; Han C; Talbot DC; Ganesan TS; Harris AL
Br J Cancer; 2000 Jun; 82(11):1759-63. PubMed ID: 10839287
[TBL] [Abstract][Full Text] [Related]
26. A feasibility study using polychemotherapy (cisplatin + vindesine + dacarbazine) plus interferon-alpha or monochemotherapy with dacarbazine plus interferon-alpha in metastatic melanoma.
Bajetta E; Del Vecchio M; Vitali M; Martinetti A; Ferrari L; Queirolo P; Sertoli MR; Cainelli T; Cellerino R; Cascinelli N
Tumori; 2001; 87(4):219-22. PubMed ID: 11693798
[TBL] [Abstract][Full Text] [Related]
27. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
Daponte A; Ascierto PA; Gravina A; Melucci MT; Palmieri G; Comella P; Cellerino R; DeLena M; Marini G; Comella G;
Cancer; 2000 Dec; 89(12):2630-6. PubMed ID: 11135225
[TBL] [Abstract][Full Text] [Related]
28. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
Johnston SR; Constenla DO; Moore J; Atkinson H; A'Hern RP; Dadian G; Riches PG; Gore ME
Br J Cancer; 1998 Apr; 77(8):1280-6. PubMed ID: 9579834
[TBL] [Abstract][Full Text] [Related]
29. Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma.
Falkson CI; Falkson G; Falkson HC
J Clin Oncol; 1991 Aug; 9(8):1403-8. PubMed ID: 2072144
[TBL] [Abstract][Full Text] [Related]
30. The addition of tamoxifen to dacarbazine and cisplatin in metastatic malignant melanoma. A phase II trial of the Southwest Oncology Group, (SWOG-8921).
Flaherty LE; Liu PY; Mitchell MS; Fletcher WS; Walker MJ; Goodwin JW; Stephens RL; Sondak VK
Am J Clin Oncol; 1996 Apr; 19(2):108-13. PubMed ID: 8610631
[TBL] [Abstract][Full Text] [Related]
31. Dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A phase I-II trial.
Ringborg U; Jungnelius U; Hansson J; Strander H
Am J Clin Oncol; 1990 Jun; 13(3):214-7. PubMed ID: 2346126
[TBL] [Abstract][Full Text] [Related]
32. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.
McDermott DF; Mier JW; Lawrence DP; van den Brink MR; Clancy MA; Rubin KM; Atkins MB
Clin Cancer Res; 2000 Jun; 6(6):2201-8. PubMed ID: 10873069
[TBL] [Abstract][Full Text] [Related]
33. A phase II study of biochemotherapy for the treatment of metastatic malignant melanoma.
Gibbs P; Iannucci A; Becker M; Allen J; O'Driscoll M; McDowell K; Williams P; Rosse P; Murphy J; Gonzalez R
Melanoma Res; 2000 Apr; 10(2):171-9. PubMed ID: 10803718
[TBL] [Abstract][Full Text] [Related]
34. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
Serrone L; Zeuli M; Sega FM; Cognetti F
J Exp Clin Cancer Res; 2000 Mar; 19(1):21-34. PubMed ID: 10840932
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of AMSA alone and in combination with DTIC in patients with metastatic melanoma.
Polyzos A; Legha SS; Burgess AM; Benjamin RS; Bodey GP
Invest New Drugs; 1988 Apr; 6(1):57-61. PubMed ID: 3410667
[TBL] [Abstract][Full Text] [Related]
36. Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomised phase III trial.
Jungnelius U; Ringborg U; Aamdal S; Mattsson J; Stierner U; Ingvar C; Malmström P; Andersson R; Karlsson M; Willman K; Wist E; Bjelkengren G; Westberg R
Eur J Cancer; 1998 Aug; 34(9):1368-74. PubMed ID: 9849419
[TBL] [Abstract][Full Text] [Related]
37. Biochemotherapy with carmustine, cisplatin, dacarbazine, tamoxifen and low-dose interleukin-2 for patients with metastatic malignant melanoma.
Su PJ; Chen JS; Liaw CC; Chang HK; Wang HM; Yang TS; Lin YC; Liau CT; Yang HY; Yeh KY; Ho MM; Chang NJ; Wang CH; Chang JW
Chang Gung Med J; 2011; 34(5):478-86. PubMed ID: 22035892
[TBL] [Abstract][Full Text] [Related]
38. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.
Atkins MB; Gollob JA; Sosman JA; McDermott DF; Tutin L; Sorokin P; Parker RA; Mier JW
Clin Cancer Res; 2002 Oct; 8(10):3075-81. PubMed ID: 12374674
[TBL] [Abstract][Full Text] [Related]
39. Effects of interferon-alpha, verapamil and dacarbazine in the treatment of advanced malignant melanoma.
Andersson R; Ake Hofer P; Riklund-Ahlström K; Henriksson R
Melanoma Res; 2003 Feb; 13(1):87-91. PubMed ID: 12569290
[TBL] [Abstract][Full Text] [Related]
40. Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma. A multicentre phase II study.
Stoter G; Shiloni E; Aamdal S; Cleton FJ; Iacobelli S; Bijman JT; Palmer P; Franks CR; Rodenhuis S
Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S41-3. PubMed ID: 2697578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
